ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO778

T Regulatory Cells in Uremia: Effect of the First Dialysis Session

Session Information

Category: Dialysis

  • 607 Dialysis: Epidemiology, Outcomes, Clinical Trials - Non-Cardiovascular

Authors

  • Caprara, Carlotta, IRRIV, Vicenza----, Italy
  • Scalzotto, Elisa, IRRIV, Vicenza----, Italy
  • Frigo, Anna chiara, University of Padova, Padova, Italy
  • Paderi, Francesca, IRRIV, Vicenza----, Italy
  • Ferrari, Fiorenza, IRRIV, Vicenza----, Italy
  • Corradi, Valentina, Hospital, San Bortolo Vicenza, Vicenza, Italy
  • Ronco, Claudio, Hospital, San Bortolo Vicenza, Vicenza, Italy
Background

In the literature, contrasting results have been reported about the influence of dialysis on Treg cells in chronic kidney disease stage G5 patients (CKD G5) that show activated but impaired immune system. Moreover the influence of dialysis on T cells needs further investigation.

Methods

A total of 22 CKD G5 patients that have to start dialysis (8 HD and 14 PD) were enrolled. Treg were studied by flow cytometry with: CD3(PerCP); CD4(FITC); CD25(PECy7); CD127(PE) and FOXP3(APC) antibodies. Time point: T0 (before the first dialysis treatment) for HD and PD; T1 (after the first dialysis); T2 (after 48 hours) and T3 (after 1 month) for HD; T1 (after 48 hours) and T2 (after 1 month) for PD.

Results

Medians for Treg/CD4+ ratio (%) in HD pts are: 7.405 (5.220; 18.940)(T0); 6.26 (3.55; 14.12)(T1), 8.140 (4.190; 17.210)(T2); 9.305 (3.840; 12.050)(T3); in PD are: 5.36 (2.96; 9.37)(T0); 4.98 (2.22; 8.69)(T1); 6.17 (1.65; 9.97)(T2). The ratio Treg/CD4 didn’t change during time of the study (HD: p= 0.6310; PD: p= 0.4191).
While, as showed in Fig.1, we observed a trend in increase Treg number, more evident in HD, between T0 and after 1 month of treatment.
Medians for Treg absolute number (cells/μl) in HD are: 349.895 (42.910; 912.240)(T0); 194.595 (57.150; 1266.850)(T1); 199.905 (43.700; 961.160)(T2); 659.60 (160.04; 1039.86)(T3); in PD are: 194.970 (16.420; 250.880)(T0); 90.535 (34.530; 444.640)(T1); 281.63 (19.75; 575.51)(T2). This difference didn’t reach significativity (HD: p= 0.16; PD: p=0.3995).

Conclusion

For the first time the same patient was analyzed during time before and after the first dialysis treatment. It seems that heamodialysis treatment improve T cells status, increasing Treg absolute number, while it does not interfere with Treg/CD4 ratio. Due to extreme variability of Treg values and poor number of patients we need further analysis.